In re­ver­sal, NICE backs Rubra­ca af­ter Clo­vis agrees to a price cut

NICE has changed its mind, agree­ing to cau­tious­ly en­dorse Clo­vis On­col­o­gy’s Rubra­ca af­ter the drug­mak­er agreed to cut its price — about two months af­ter the UK cost-ef­fec­tive­ness agency’s ini­tial re­jec­tion.

Rubra­ca, known chem­i­cal­ly as ru­ca­parib, is ap­proved for use in the EU as monother­a­py for the main­te­nance treat­ment of adult pa­tients with high-grade ep­ithe­lial ovar­i­an, fal­lop­i­an tube, or pri­ma­ry peri­toneal can­cer who have re­lapsed af­ter plat­inum-based chemother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.